The 4th Next Generation Gene Therapy Vectors Summit is just around the corner! Delivery is cited by many in the gene therapy field as the limiting factor for R&D progress. As such, significant attention and investment continue to pour into improving the safety, tissue-targeting, and translatability of delivery platforms.
In this context, this year’s summit will be uniting R&D and business development leaders to advance cutting-edge delivery platforms into the clinic, leveraging the latest case studies into innovative capsid and payload design.
Attendees can expect a dynamic program, with new data readouts from clinically-validated novel vectors along with expert-led group discussions, leaving them with actionable insights to level up their own delivery platforms.
Renowned speakers from biopharma, academia and VCs will share exclusive case studies and insights including:
- Capsid Discovery and engineering work: improving tissue and cell targeting, evading the immune system, and exploring machine-guided design
- Payload Design: leveling up cassette engineering and enabling controllable transgene expression to improve safety and expression profiles
- Scalable and Cost-Effective Manufacturability: unlocking productive manufacturability downstream through smart vector development and selection upstream
- Immunogenicity and Toxicity Concerns: overcoming immune responses to IV-administered AAV vectors with improved capsid engineering, payload design, and tissue tropism validation efforts
- Investor Insights: understand VC and big pharma’s perspectives on what drives a high-value proposition for securing investment, acquisitions, and mergers
See the full agenda & speaker line up here.
If you are working to enable targeted gene delivery, expand packaging capacities, and enhance the manufacturability for safe, cost-effective, and translatable delivery platforms, this is your only conference opportunity.
Join us at the Next Generation Gene Therapy Vectors Summit to level up your vector development efforts.